Induction of endogenous γ-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence
Open Access
- 27 March 2009
- journal article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 2 (1), 15
- https://doi.org/10.1186/1756-8722-2-15
Abstract
Human β-globin disorders are relatively common genetic diseases cause by mutations in the β-globin gene. Increasing the expression of the γ-globin gene has great benefits in reducing complications associated with these diseases. The Oct-1 transcription factor is involved in the transcriptional regulation of the γ-globin gene. The human γ-globin genes (both Aγ and Gγ-globin genes) carry three Oct-1 transcription factor consensus sequences within their promoter regions. We have studied the possibility of inducing γ-globin gene expression using decoy oligonucleotides that target the Oct-1 transcription factor consensus sequence. A double-stranded 22 bp decoy oligonucleotide containing the Oct-1 consensus sequence was synthesized. The results obtained from our in vitro binding assay revealed a strong competitive binding of the decoy oligonucleotide for the Oct-1 transcription factor. When K562 human erythroleukemia cells were treated with the Oct-1 decoy oligonucleotide, significant increases in the level of the γ-globin mRNA were observed. The results of our western blots further demonstrated significant increases of the fetal hemoglobin (HbF, α2γ2) in the Oct-1 decoy oligonucleotide-treated K562 cells. The results of our immunoprecipitation (IP) studies revealed that the treatment of K562 cells with the Oct-1 decoy oligonucleotide significantly reduced the level of the endogenous γ-globin gene promoter region DNA co-precipitated with the Oct-1 transcription factor. These results suggest that the decoy oligonucleotide designed for the Oct-1 transcription factor consensus sequence could induce expression of the endogenous γ-globin gene through competitive binding of the Oct-1 transcription factor, resulting in activation of the γ-globin genes. Therefore, disrupting the bindings of the Oct-1 transcriptional factors with the decoy oligonucleotide provides a novel approach for inducing expression of the γ-globin genes. It also provides an innovative strategy for the treatment of many disease conditions, including sickle cell anemia and β-thalassemia.Keywords
This publication has 45 references indexed in Scilit:
- Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?Drug Discovery Today, 2008
- Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA virusesAntiviral Research, 2008
- The versatility of oligonucleotides as potential therapeuticsExpert Opinion on Biological Therapy, 2007
- Transcription factor decoy oligonucleotide-based therapeutic strategy for renal diseaseClinical and Experimental Nephrology, 2007
- Molecular therapies in β‐thalassaemiaBritish Journal of Haematology, 2006
- Tissue fibrosis and carcinogenesis: Divergent or successive pathways dictate multiple molecular therapeutic targets for oligo decoy therapiesJournal of Cellular Biochemistry, 2006
- Downregulation of TNF-α and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumorGene Therapy, 2003
- The virtuoso of versatility: POU proteins that flex to fitJournal of Molecular Biology, 2000
- Activation of human γ-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ-globin gene 5′ flanking regionGene, 2000
- Role of AP-1 Complex in Angiotensin II-Mediated Transforming Growth Factor-β Expression and Growth of Smooth Muscle Cells: Using Decoy Approach against AP-1 Binding SiteBiochemical and Biophysical Research Communications, 1998